Neoadjuvant Sugemalimab + Chemotherapy Followed by Adjuvant Sugemalimab for Patients With Resectable Stage II-IIIA Non-small-cell Lung Cancer Patients

Inclusion criteria

• Age ≥ 18 years
• Patients have voluntarily to join the study and give written informed consent for the study.
• Histologically documented, stage II-IIIA Non-Small Cell Lung Cancer (according to version 9th of the International Association for the Study of Lung Cancer Staging Manual in Thoracic Oncology) and previously untreated.
• Tumor should be considered resectable before study entry by a multidisciplinary team.
• ECOG Performance Status of 0 or 1
• At least 1 unidimensional measurable lesion meeting Response Evaluation Criteria in Solid Tumours (RECIST) criteria.
• Able to comply with study and follow-up procedures
• Major organ function For regular test results（no blood transfusion within 14 days）：

• Hemoglobin（HB）≥90g/L；
• Absolute neutrophils count（ANC）≥1.5×109/L；
• Blood platelets（PLT）≥100×109/L

Biochemical tests results defined as follows:

• Total bilirubin（TBIL）≤1.5 times the upper limit of normal (ULN) ；
• Alanine aminotransferase (ALT) and aspartate aminotransgerase AST≤2.5*ULN,
• Creatinine（Cr）≤1.5*ULN or Creatinine Clearance rate (CCr)≥60 ml/min; Coagulation test: INR/APTT within normal limits Doppler ultrasound assessment：left ventricular ejection fraction (LVEF) ≥the lower limit of normal value (50%).
• The patients need to have a forced expiratory volume (FEV1) ≥ 1.2 liters
• Subjects must provide fresh tissues or formalin-fixed tumor tissue samples at or the diagnosis NSCLC for mIF.

Exclusion criteria

• 1) All patients carrying activating mutations in the TK domain of EGFR or any variety of alterations in the ALK gene.

• Small cell lung cancer (including patients with mixed small cell lung cancer and non-small cell lung cancer).

• Any anti-tumor treatment within the past 5 years, including chemotherapy, radiotherapy, target therapy or other immunotherapy 4) Severe acute or chronic infections, including: hepatits B, hepatits C, HIV etc 5) Patients with active, known or suspected autoimmune disease. Subjects with vitiligo, type I diabetes mellitus, residual hypothyroidism due to autoimmune thyroiditis only requiring hormone replacement or unexpected conditions of recurrence in the absence of an external trigger are allowed to be included.

• Histologically confirmed adenosquamous carcinoma 7) Any prior treatment of antibody/drug that targets at T-cell coregulatory proteins 8) Subjects have interstitial lung disease (ILD), or a history of ILD that required corticosteroid treatment.

• Women in pregnancy or lactation. 10) Patients who are allergic to any of the agent or any ingredient